National Institute for Health and Care Research (NIHR)

This sponsor has funded 5 studies across 29 countries.

PAS funded by this sponsor.
EU PAS ID Status RMP requirement Title Protocol uploaded Results uploaded
10029 Finalised Non-EU RMP-only Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study No No
18006 Ongoing Not included in RMP Intended and unintended effects of Z-drug use for sleep disturbance in people with dementia – ‘Z-drug Evaluation in Dementia’ (ZED) Yes No
35413 Ongoing Not included in RMP Development of a Multivariable Model to Predict the Risk of Dose Delays following Chemotherapy No No
35860 Planned Not included in RMP The PsoProtect Research Database (Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of Covid-19 infecTion) No No
38362 Ongoing Not included in RMP The risk of musculoskeletal adverse outcomes after treatment with endocrine blocking treatments for breast cancer (MSKAI) Yes No

PAS by Risk Management Plan (RMP) requirement

National Institute for Health and Care Research (NIHR)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.